【佳學(xué)基因檢測】癲癇患者做完基因檢測后如何調(diào)整苯妥英鈉的藥物劑量？
The patient population included adult individuals of primarily European ancestry enrolled in a retrospective observational study of adult and pediatric chronic epilepsy patients followed by epileptologists at Duke University Medical Center (n 79), and the National Hospital for Neurology and Neurosurgery, University College London Hospital (n 94). Studies were performed under protocols approved by the appropriate local institutional review boards. Informed consent was either obtained from each patient or from the patients’ parent or caregiver when it was not possible to obtain consent from the patient directly. A DNA sample was obtained from each patient, and medical records were reviewed retrospectively. Selected clinical data including a comprehensive past medical history and demographic information, epilepsy diagnosis, seizure type and frequency, drug initiation and stop dates, and adverse effects from AEDs were recorded in a relational database (InForm). We tested whether concomitant antiepileptic medications, or any individual AED, in particular, was associated with PHT maintenance dose; however, these variables did not significantly predict PHT dose requirements. Thus, we treated all individuals achieving the maintenance dose definition as a group, and ignored the potential influence of concomitant medications as a practical measure in our analysis. Genotyping for CYP2C9*2, CYP2C9*3, and CYP2C9-3089GA was performed by use of Taqman MGB genotyping assays (Applied Biosystems)(責(zé)任編輯：佳學(xué)基因)
